<DOC>
	<DOC>NCT00357370</DOC>
	<brief_summary>The purpose of this clinical research study is to learn if BMS-512148, added to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone), can help reduce the blood sugar levels compared to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone) alone, in subjects with type 2 diabetes. The safety of this treatment will also be studied.</brief_summary>
	<brief_title>A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Males and females, 18 to 75 years old, with type 2 diabetes with inadequate glycemic control Subjects receiving insulin and metformin and/or a thiazolidinedione Body Mass Index &lt;=45.0 kg/m2 Serum creatinine &lt;1.5 mg/dL for men or &lt;1.4 mg/dL for women No overt proteinuria (in subjects with a microalbumin/creatinine ratio ≥300 mg/g, the 24hour urinary excretion of total protein must be &lt;3 g/24 hrs) History of type 1 diabetes AST and/or ALT &gt;2.5 times the upper limit of normal Creatinine kinase ≥3 times the upper limit of normal Symptoms of severely uncontrolled diabetes History of hypoglycemic unawareness Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>